Real-World Experience with Dupilumab in Severe Asthma: One-Year Data from an Italian Named Patient Program.
Raffaele CampisiClaudia CrimiSanti NolascoBianca BeghèLeonardo AntonicelliGabriella GuarnieriNicola ScichiloneMorena PortoLuigi MacchiaGiulia SciosciaMaria Pia Foschino BarbaroAlberto PapiNunzio CrimiPublished in: Journal of asthma and allergy (2021)
Dupilumab improved all the explored clinical outcomes after 12 months, and the transient hypereosinophilia did not modify treatment response. These real-world data confirm the results reported in randomized controlled trials and provide an important opportunity to characterize the clinical impact of the treatment in a non-trial setting. Further real-world studies with a larger cohort of patients are needed to confirm these findings.
Keyphrases
- end stage renal disease
- atopic dermatitis
- randomized controlled trial
- electronic health record
- ejection fraction
- newly diagnosed
- chronic kidney disease
- big data
- prognostic factors
- peritoneal dialysis
- study protocol
- clinical trial
- quality improvement
- systematic review
- phase ii
- patient reported outcomes
- open label
- replacement therapy
- smoking cessation